GenMark Diagnostics (GNMK) Reports In-Line Q4 EPS

GenMark Diagnostics (NASDAQ: GNMK) reported Q4 EPS of ($0.27), in-line with the analyst estimate of ($0.27). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $14.83 million.

For earnings history and earnings-related data on GenMark Diagnostics (GNMK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c